GemCap Biotech ApS: Financial statements 2022
CVR: 38189174
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
GemCap Biotech ApS (CVR 38189174) has filed annual accounts for 2022. In 2022, the company reported a net result of EUR 0 compared with EUR 0 the year before. Equity in the 2022 report amounted to EUR 27,000. The solvency ratio was 100%.
- Profit/Loss
- EUR 0
- Equity
- EUR 27,000
- Total Assets
- EUR 27,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | 0 EUR | 27 t. EUR | - |
| 2021 | - | - | 0 EUR | 7 t. EUR | - |
| 2020 | - | - | 0 EUR | 7 t. EUR | - |
| 2019 | - | - | 0 EUR | 7 t. EUR | - |
| 2018 | - | - | 0 EUR | 7 t. EUR | - |
Official annual report
Keep an eye on GemCap Biotech ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
GemCap Biotech ApS has published its annual report for 2021. The net result was DKK 0.
About GemCap Biotech ApS
GemCap Biotech ApS was a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company has been dissolved on 24 March 2024. The company was registered under the industry Anden finansiel formidling undtagen forsikring og pensionsforsikring, i.a.n.. According to the 2023 annual report, the company had an average of 0 employees. In 2023, the company reported a net result of EUR 0 compared with EUR 0 the year before. Equity in the 2023 report amounted to EUR 27,000.